Jane Street
DYN icon

Jane Street’s Dyne Therapeutics DYN Stock Holding History

Jane Street’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-70,323
Closed -$1.21M – 11893
2025
Q4 		$1.38M Sell
70,323
-211,017
-75% -$4M ﹤0.01% 5502
2025
Q3 		$3.56M Buy
281,340
+152,378
+118% +$1.74M ﹤0.01% 3945
2025
Q2 		$1.23M Buy
128,962
+11,956
+10% +$132K ﹤0.01% 5241
2025
Q1 		$1.22M Sell
117,006
-11,284
-9% -$161K ﹤0.01% 5190
2024
Q4 		$3.02M Buy
128,290
+23,773
+23% +$703K ﹤0.01% 3428
2024
Q3 		$3.75M Sell
104,517
-110,954
-51% -$4.42M ﹤0.01% 3333
2024
Q2 		$7.6M Buy
215,471
+127,948
+146% +$3.72M ﹤0.01% 2366
2024
Q1 		$2.48M Buy
87,523
+69,040
+374% +$1.56M ﹤0.01% 3749
2023
Q4 		$246K Sell
18,483
-32,738
-64% -$320K ﹤0.01% 7923
2023
Q3 		$459K Buy
+51,221
New +$552K ﹤0.01% 6428
2023
Q2 		– Sell
-27,629
Closed -$318K – 8850
2023
Q1 		$318K Sell
27,629
-68,122
-71% -$885K ﹤0.01% 7095
2022
Q4 		$1.11M Buy
+95,751
New +$1.11M ﹤0.01% 4824

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Jane Street's DYN Position: Q1 2026 in Review

Jane Street sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 70,323 shares — an estimated $1.21M sold.

Jane Street first reported a position in DYN in Q4 2022 and held it in 12 quarters. The position peaked at $7.6M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Jane Street reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 70,323 Dyne Therapeutics shares in Q1 2026, an estimated $1.21M.
  • Jane Street first reported a position in Dyne Therapeutics in Q4 2022 and held it in 12 quarters.
  • Jane Street's Dyne Therapeutics position peaked at $7.6M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.